A simple, accurate reversed-phase high-performance liquid chromatography method was developed and validated for simultaneous determination of gliclazide (GLZ) and fluoroquinolone antibacterial levofloxacin (LVO). The method was developed by using a stainless steel analytical column , C18 (250,4.6 mm,5µm). The system was operated using a mobile phase consisting of methanol and phosphate buffer (pH 3.0) at a flow rate of 0.8mL minˉ1 with ultraviolet detection monitored at wavelength 228 nm. The above method was validated using ICH analytical method validation guidelines. Utilizing HPLC techniques, an assay was intended to determine in vitro effects of levofloxacin on sulphonyl urea an anti-diabetic gliclazide. Obtained results were further verified with UV spectrophotometric method. Availability of gliclazide was reduced in the presence of levofloxacin. This in vitro analyses confirms the co-administration of gliclazide and levofloxacin and may serve for designing further in vivo studies.
Previous Article in event
A stability indicating RP-HPLC method development and validation for the estimation of combined tablet formulation of Amlodipine & CandesartanPrevious Article in session
Next Article in event
New 2-alkylthio-4-chlorobenzenesulfonamide derivatives bearing heterocyclic moieties – synthesis, structure and anticancer activity studiesNext Article in session
In vitro drug-drug interaction studies of Gliclazide with Levofloxacin by using HPLC: guidelines for co-prescription drugs
Published: 31 October 2018 by MDPI in 4th International Electronic Conference on Medicinal Chemistry session Posters
Keywords: drug drug interactions , co-prescription drugs ,In-vitro models , Pharmacokinetics and HPLC